Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis

被引：0
|
作者：
Altmann, Dan [1 ]
Jasperse, B. [2 ]
Barkhof, Frederik [2 ]
Beckmann, Karola [3 ]
Filippi, Massimo [6 ]
Kappos, Ludwig [4 ]
Molyneux, P. [1 ]
Polman, Chris H. [2 ]
Pozzilli, Carlo [5 ]
Thompson, Alan J. [1 ]
Wagner, Klaus [3 ]
Yousry, Tarek [1 ]
Miller, David H. [1 ]
机构：
[1] UCL Inst Neurol, Med Ctr, London WC1N 3BG, England
[2] Vrije Univ Amsterdam, Amsterdam, Netherlands
[3] Bayer HealthCare, Berlin, Germany
[4] Univ Basel Hosp, CH-4031 Basel, Switzerland
[5] Univ Roma La Sapienza, Rome, Italy
[6] Univ Osped San Raffaele, Milan, Italy
来源：
MULTIPLE SCLEROSIS JOURNAL | 2008年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S22 / S22
页数：1
相关论文
共 50 条
  • [21] OUTCOME MEASURES FOR CLINICAL-TRIALS IN MULTIPLE-SCLEROSIS - REPLY
    MCFARLAND, HF
    [J]. ANNALS OF NEUROLOGY, 1992, 31 (01) : 116 - 117
  • [22] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Uitdehaag, Bernard M. J.
    [J]. CNS DRUGS, 2018, 32 (06) : 543 - 558
  • [23] Appropriate design and outcome measures in multiple sclerosis clinical trials - Response
    Khan, OA
    Tselis, AC
    Kamholz, JA
    Garbern, JY
    Lewis, RA
    Lisak, RP
    [J]. EUROPEAN JOURNAL OF NEUROLOGY, 2001, 8 (05) : 505 - 506
  • [24] Disability Outcome Measures in Phase III Clinical Trials in Multiple Sclerosis
    Bernard M. J. Uitdehaag
    [J]. CNS Drugs, 2018, 32 : 543 - 558
  • [25] Volumes of brain atrophy and plaques correlated with neurological disability in secondary progressive multiple sclerosis
    Dastidar, P
    Heinonen, T
    Lehtimäki, T
    Ukkonen, M
    Peltola, J
    Erilä, T
    Laasonen, E
    Elovaara, I
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1999, 165 (01) : 36 - 42
  • [26] Alterations in major neurochemical levels and correlation with brain atrophy in secondary progressive multiple sclerosis
    Lee, P.
    Lynch, S.
    Denney, D.
    Choi, I.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S384 - S384
  • [27] Clinical outcome measures for progressive MS trials
    Ontaneda, Daniel
    Cohen, Jeffrey A.
    Amato, Maria Pia
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (12) : 1627 - 1635
  • [28] Spinal cord atrophy as a primary outcome measure in phase II trials of progressive multiple sclerosis
    Cawley, Niamh
    Tur, Carmen
    Prados, Ferran
    Plantone, Domenico
    Kearney, Hugh
    Abdel-Aziz, Khaled
    Ourselin, Sebastian
    Wheeler-Kingshott, Claudia A. M. Gandini
    Miller, David H.
    Thompson, Alan J.
    Ciccarelli, Olga
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (07) : 932 - 941
  • [29] Spinal cord atrophy as a primary outcome measure in primary progressive multiple sclerosis neuroprotective trials
    Cawley, N.
    Abdel-Aziz, K.
    Schneider, T.
    Altmann, D.
    Wheeler-Kingshott, C. A. M.
    Miller, D. H.
    Thompson, A. J.
    Ciccarelli, O.
    [J]. MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 189 - 190
  • [30] Severe Progressive Brain Atrophy in Pediatric Multiple Sclerosis
    Bhise, Vikram
    Buyukturkoglu, Korhan
    Inglese, Matilde
    Wollack, Jan B.
    Balashov, Konstantin
    [J]. JOURNAL OF PEDIATRIC NEURORADIOLOGY, 2015, 4 (02) : 32 - 35
12345